USFDA approval for Orchid
By Our Corporate Bureau | 05 Dec 2003
Chennai: Orchid Chemicals & Pharmaceuticals, a city-based bulk drug major, has formally received the approval from the United States Food and Drugs Administration (USFDA) for its sterile API (active pharmaceutical ingredient) product Cefazolin.
The USFDA authorities inspected the plant this September. An important sterile cephalosporin antibiotic API, Cefazolin is used in the treatment of several infections. Orchid has established world-class sterile lyophilisation and non-sterile facilities for integrated manufacture of this product.
"This is definitely a very key development for Orchid and another significant milestone in our regulatory roadmap. This approval will enable a strong entry for our sterile injectable product, Cefazolin, into the US market. We hope to start exports of this product to the US soon," says Orchid managing director Raghavendra Rao.
Latest articles
Featured articles
The analog antidote: why Americans are trading algorithms for physical media
By Cygnus | 16 Feb 2026
Vinyl, books, and DVDs are seeing renewed interest as Americans seek ownership, focus, and a break from screen fatigue in an increasingly digital world.
China opens market to 53 African nations in zero-tariff pivot
By Cygnus | 16 Feb 2026
China will grant zero-tariff access to 53 African nations from May 2026, reshaping global trade ties and deepening economic links across the Global South.
The deregulation “holy grail”: Trump EPA dismantles the legal bedrock of climate policy
By Cygnus | 13 Feb 2026
The Trump EPA moves to rescind the 2009 Endangerment Finding, reshaping federal climate authority and business risk.
Tokenising the gilt: what the UK’s digital bond pilot could mean for sovereign debt
By Cygnus | 12 Feb 2026
HM Treasury selects HSBC Orion and Ashurst LLP for its Digital Gilt Instrument (DIGIT) pilot. A deep dive into the architecture, legal framework, and the shift toward near real-time settlement.
The silicon-rich AI race: how Cisco’s G300 puts networking at the center of compute
By Cygnus | 11 Feb 2026
Cisco's new Silicon One G300 targets AI data center bottlenecks as networking becomes central to compute performance.
Server CPU Shortages Grip China as AI Boom Strains Intel and AMD Supply Chains
By Cygnus | 06 Feb 2026
Intel and AMD server CPU shortages are hitting China as AI data center demand surges, pushing lead times to six months and driving prices higher.
Budget 2026-27 Seeks Fiscal Balance Amid Rupee Volatility and Industrial Stagnation
By Cygnus | 02 Feb 2026
India's Budget 2026-27 targets fiscal discipline with record capex as markets tumble, the rupee weakens and manufacturing struggles to regain momentum.
The Thirsty Cloud: Why 2026 Is the Year AI Bottlenecks Shift From Chips to Water
By Axel Miller | 28 Jan 2026
As AI server density surges in 2026, data centers face a new bottleneck deeper than chips — the massive water demand required for cooling next-generation infrastructure.
The New Airspace Economy: How Geopolitics Is Rewriting Aviation Costs in 2026
By Axel Miller | 22 Jan 2026
Airspace bans, sanctions and corridor risk are forcing airlines into costly detours in 2026, raising fuel burn, reducing aircraft utilisation and pushing airfares higher worldwide.
Latest articles
